Bisphosphonates: mechanisms of action.
作者信息
Rodan G A, Fleisch H A
机构信息
Department of Bone Biology & Osteoporosis, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
出版信息
J Clin Invest. 1996 Jun 15;97(12):2692-6. doi: 10.1172/JCI118722.
Abstract
摘要
相似文献
1
Bisphosphonates: mechanisms of action.双膦酸盐：作用机制
J Clin Invest. 1996 Jun 15;97(12):2692-6. doi: 10.1172/JCI118722.
2
Molecular mechanisms of action of bisphosphonates.双膦酸盐的分子作用机制。
Bone. 1999 May;24(5 Suppl):73S-79S. doi: 10.1016/s8756-3282(99)00070-8.
3
Mechanisms of action of the bisphosphonates.双膦酸盐的作用机制。
Medicina (B Aires). 1997;57 Suppl 1:65-75.
4
Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.
Horm Metab Res. 1997 Mar;29(3):145-50. doi: 10.1055/s-2007-979008.
5
Bisphosphonate therapy.双膦酸盐治疗
Am J Med Sci. 1997 Jan;313(1):17-22. doi: 10.1097/00000441-199701000-00004.
6
Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
Calcif Tissue Int. 1991 Dec;49(6):407-15. doi: 10.1007/BF02555852.
7
[Mechanisms for anti-resorptive action of bisphosphonates in bone diseases].[双膦酸盐在骨疾病中的抗吸收作用机制]
Postepy Biochem. 2001;47(4):328-36.
8
[Inhibitory effects of bisphosphonates on bone resorption].双膦酸盐对骨吸收的抑制作用
Nihon Yakurigaku Zasshi. 1995 May;105(5):285-94. doi: 10.1254/fpj.105.285.
9
Current controversies in bisphosphonate therapy.双膦酸盐治疗中的当前争议。
Orthopedics. 2010 Jul;33(7):468. doi: 10.3928/01477447-20100526-01.
10
Morphometric evidence that YM175, a bisphosphonate, reduces trabecular bone resorption in ovariectomized dogs with dietary calcium restriction.形态学证据表明，双膦酸盐YM175可减少饮食中钙受限的去卵巢犬的小梁骨吸收。
Jpn J Pharmacol. 1999 Mar;79(3):397-400. doi: 10.1254/jjp.79.397.
引用本文的文献
1
Bone and Cardiometabolic Connection: Crosstalk between Osteoporosis and Atherosclerosis.骨骼与心脏代谢的联系：骨质疏松症与动脉粥样硬化之间的相互作用
Cell Biochem Biophys. 2025 Aug 13. doi: 10.1007/s12013-025-01851-x.
2
A Systematic Review on the Efficacy of Bisphosphonates on Osteogenesis Imperfecta.双膦酸盐治疗成骨不全症疗效的系统评价
Cureus. 2025 Jun 22;17(6):e86549. doi: 10.7759/cureus.86549. eCollection 2025 Jun.
3
Effects of clodronate disodium on endocrine regulators of calcium in yearling horses.氯膦酸二钠对一岁马钙内分泌调节因子的影响。
J Anim Sci. 2025 Jan 4;103. doi: 10.1093/jas/skaf132.
4
Evaluation of Zoledronate for Pain Suppression in Diffuse Sclerosing Osteomyelitis of the Mandible: Protocol for a Prospective, Single-Arm Interventional Study.唑来膦酸对下颌骨弥漫性硬化性骨髓炎疼痛抑制作用的评估：一项前瞻性单臂干预研究方案
Cureus. 2025 Mar 17;17(3):e80739. doi: 10.7759/cureus.80739. eCollection 2025 Mar.
5
Potential of zoledronate for treating diffuse sclerosing osteomyelitis of the mandible in adult patients.唑来膦酸盐治疗成年患者下颌骨弥漫性硬化性骨髓炎的潜力。
Clin Rheumatol. 2025 Jun;44(6):2463-2475. doi: 10.1007/s10067-025-07438-4. Epub 2025 Apr 16.
6
Alterations of bone proteins in medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死中骨蛋白的改变
Eur J Oral Sci. 2025 Apr;133(2):e70003. doi: 10.1111/eos.70003. Epub 2025 Feb 19.
7
Considerations for oral and dental tissues in holistic care during long-haul space flights.长途太空飞行期间整体护理中口腔和牙齿组织的考量因素。
Front Physiol. 2024 Jul 11;15:1406631. doi: 10.3389/fphys.2024.1406631. eCollection 2024.
8
A case of successful treatment of medication-related osteonecrosis of the jaw with conservative treatment for pathological mandibular fracture.1例药物相关性颌骨坏死合并病理性下颌骨骨折经保守治疗成功治愈的病例。
Int J Surg Case Rep. 2024 Jul;120:109822. doi: 10.1016/j.ijscr.2024.109822. Epub 2024 May 31.
9
The multi-faceted nature of age-associated osteoporosis.年龄相关性骨质疏松症的多方面特性。
Bone Rep. 2024 Mar 5;20:101750. doi: 10.1016/j.bonr.2024.101750. eCollection 2024 Mar.
10
A narrative review of the pharmaceutical management of osteoporosis.骨质疏松症药物治疗的叙述性综述。
Ann Jt. 2023 Jun 20;8:25. doi: 10.21037/aoj-23-2. eCollection 2023.
本文引用的文献
1
Studies on x ray absorption and diffraction of bone tissue.骨组织的X射线吸收与衍射研究。
Acta Anat (Basel). 1952;15(1-2):1-22. doi: 10.1159/000140734.
2
Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates.人蛋白酪氨酸磷酸酶-σ：可变剪接及双膦酸盐的抑制作用
J Bone Miner Res. 1996 Apr;11(4):535-43. doi: 10.1002/jbmr.5650110415.
3
A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates.一种调节骨吸收的新模型，特别涉及双膦酸盐的作用。
J Bone Miner Res. 1996 Feb;11(2):150-9. doi: 10.1002/jbmr.5650110203.
4
Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.
Bone. 1996 Jan;18(1):9-14. doi: 10.1016/8756-3282(95)00426-2.
5
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.双膦酸盐在体外和体内均可促进小鼠破骨细胞凋亡。
J Bone Miner Res. 1995 Oct;10(10):1478-87. doi: 10.1002/jbmr.5650101008.
6
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.双膦酸盐可诱导成骨细胞分泌一种破骨细胞介导的骨吸收抑制剂。
Endocrinology. 1996 Jun;137(6):2324-33. doi: 10.1210/endo.137.6.8641182.
7
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate.蛋白酪氨酸磷酸酶活性调节破骨细胞的形成和功能：阿仑膦酸盐的抑制作用。
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. doi: 10.1073/pnas.93.7.3068.
8
A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.双膦酸盐对破骨细胞的特异性作用的一种可能机制：替鲁膦酸优先影响具有皱褶缘的极化破骨细胞。
Bone. 1995 Aug;17(2):137-44. doi: 10.1016/s8756-3282(95)00150-6.
9
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.双膦酸盐通过成骨细胞的介导作用于大鼠的骨吸收。
J Clin Invest. 1993 May;91(5):2004-11. doi: 10.1172/JCI116422.
10
Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.间歇性周期性依替膦酸长期治疗绝经后骨质疏松症后骨组织形态计量学的变化
J Bone Miner Res. 1993 Feb;8(2):199-208. doi: 10.1002/jbmr.5650080211.
Zotero 插件